

14/08/2015 – Sexta-Feira

14:00 - 15:00	Tema científico	
15:00 - 16:00	Tema científico	
16:00 - 16:35	Coffee Break	
Horário	Módulo	Aula
16:35 - 17:15	Gastrointestinal (Noncolorectal câncer)	LBA 101: Phase I/II safety and antitumor activity of Nivolumab in patients with advanced HCC: CA 209-040
		Abstract 4001: Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE 012
		Abstract 4003 : INTEGRATE : A randomized phase II double-blind , placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) : A study by the Australasian Gastrointestinal Trials Group (AGITG) - Final overall and subgroup results
		Abst 4005: Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 ( Alliance)
17:15 - 17:45		Discussão
17:45 - 18:10	Hematology	Phase I Clinical Trial of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed or Refractory B-ALL
		Phase IIA Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas
		Phase 2 Study of Daratumumab (DARA) in patients with >= 3 lines of Prior Therapy or Double Refractory Multiple Myeloma: 54767414MMY2002 (Sirius)
18:10 - 18:30		Discussão
18:30 - 19:00	Triple negative Breast Cancer	Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician's Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study
		Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC)
		Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
		The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast
19:00 - 19:30		Discussão
19:30	Abertura	

15/08/2015 - Sábado

Horário	Módulo	Aula
08:00 - 08:45	Genitourinary cancer	Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476)
		Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—NCT00423475
		A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521)
		Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)
		Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN)
		A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients
08:45 - 09:15		<b>Discussão</b>
09:15 - 09:45	Imunotherapy and Lung Cancer	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)
		Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR)
		Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028
		Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
09:45 - 10:15		<b>Discussão</b>
10:15- 10:30	<b>Coffe Break</b>	
10:30 - 11:00	Head and Neck	Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A randomised control trial (RCT)
		Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma
		Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort
		PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT)
11:00 - 11:30		<b>Discussão</b>

Horário	Módulo	Aula
11:30 - 12:00	Gynecologic	A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P
		Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis
		Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial
12:00 - 12:30		<b>Discussão</b>
12:30 - 14:00	Lunch	
14:00 - 14:30	Target therapy, chemotherapy and radiotherapy in Lung Cancer	Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts)
		Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC)
		NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases
		Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC)
14:30 - 15:00		<b>Discussão</b>
15:00-15:30	Breast Cancer ER+/Her2 +	Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study
		Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)
		Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy
		PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy
15:30 - 16:00		<b>Discussão</b>
16:00 - 16:15	Coffe Break	

Horário	Módulo	Aula
16:15 - 16:53	<b>Gastrointestinal (Colorectal)</b>	Abstract 3500 - A multicenter randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results
		Abstract 3501 - Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC-LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)
		Abstract 3502 - SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 +/- bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) +/- bev in patients with metastatic colorectal cancer (mCRC)
		Abstract 3508: Trastuzumab and Lapatinib in HER-2 amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial
		LBA 100: PD-1 Blockade in tumors with mismatch repair deficiency
16:53 - 17:15		<b>Discussão</b>
17:15-17:30	<b>Paliative Care</b>	Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2)
		CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer
17:30 - 17:45		<b>Discussão</b>
17:45 - 18:15	<b>Melanoma</b>	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
		Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
		Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial
18:15 - 18:45		<b>Discussão</b>
18:45	<b>Encerramento</b>	